Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment

• DOI: 10.2337/diab.46.2.265
• Publication Date: 2013-09-19T17:42:54Z
• Authors: James H Anderson; Rocco L Brunelle; Veikko A Koivisto; Andreas Pfützner; Michael E Trautmann; Louis Vignati; Richard DiMarchi
• Keywords: Insulin lispro; Crossover study; Regular insulin; Insulin analog

Insulin lispro, an insulin analog recently developed particularly for mealtime therapy, has a fast absorption rate and short duration of action. We compared lispro regular human in the treatment 1,008 patients with IDDM. The study was 6-month randomized multinational (17 countries) multicenter (102 investigators) clinical trial performed open-label crossover design. injected immediately before meal, 30–45 min meal. Throughout study, postprandial rise serum glucose significantly lower during therapy. At endpoint, reduced at 1 h by 1.3 mmol/l 2 2.0 treated (P < 0.001). hypoglycemia 12% less (6.4 ± 0.2 vs. 7.2 0.3 episodes/30 days, P 0.001), independent basal regimen or HbA1c level. reduction observed equally episodes without symptoms. When total number each patient analyzed according to time occurrence, hypoglycemic than therapy three four quarters day largest relative improvement night. In conclusion, improves control, reduces episodes, convenience, insulin, IDDM patients.